Diagnosis and treatment of obstructive sleep apnoea in patients with head and neck squamous cell carcinoma treated with surgery and adjuvant radiation therapy
Organizational Data
- DRKS-ID:
- DRKS00021692
- Recruitment Status:
- Recruiting ongoing
- Date of registration in DRKS:
- 2020-05-26
- Last update in DRKS:
- 2021-07-20
- Registration type:
- Prospective
Acronym/abbreviation of the study
KKHR-OSA-Surg
URL of the study
No Entry
Brief summary in lay language
The study aims to examine patients with head and neck squamous cell carcinoma (HNSCC) treated with standard surgery followed by radiation (and possibly chemotherapy) for concomitant obstructive sleep apnea (OSA). To this end 200 patients will be randomized into two groups, who either receive the standard therapy of OSA – an auto-titrating positive pressure therapy (aPAP) – in parallel with the radiation therapy or who do not receive this therapy. The primary endpoint is the EORTC QLQ c30 questionnaire with the symptoms scale fatigue. Other endpoints include the apnea/hypopnea index (the standard of severity classification of OSA), cancer-related survival/recurrence, and other patient-reported complaints, which are recorded with the other scales of the EORTC and additional questionnaires on fatigue, insomnia, physical function, daytime sleepiness, and general sleep quality. For this purpose, an outpatient sleep examination with corresponding survey via questionnaires is carried out in the patients at five different times during the study (before the start of therapy, after surgery, after radiation and 3 and 6 months after completion of the cancer treatment). For sleep examination, patients are given a home sleep apnea testing device that measures nasal respiratory flow, oxygen saturation in the blood, chest and abdominal movement, brain currents and muscle tension. The aim of the study is to obtain reliable knowledge about the comorbid OSA and its therapy with positive pressure therapy in patients with KHP, with particular consideration given to the development of quality of life with and without treatment. In addition, the effect of the treatment of OSA on overall survival or cancer recurrence rate will be investigated.
Brief summary in scientific language
In this randomized, controlled trial the effect of OSA treatment with nocturnal auto-titrated positive airway pressure (aPAP) therapy in patients with comorbid OSA (diagnosed by portable polysomnography, PSG) and cT2-cT4 HNSCC irrespective of N-nodal status undergoing surgical and adjuvant radiation cancer therapy will be investigated. Participants in the intervention group are going to be treated with aPAP during the course of adjuvant radiation therapy (with or without concurrent chemo- or immune-therapy) and for the 6 months following termination of radiation. End points include: patient-reported outcomes (PROs), namely the Symptom Scale Fatigue of EORTC QLQ-C30 version 3.0 questionnaire (primary end point), the other symptom scales of the EORTC questionnaire, the apnea / hypopnea index (AHI) as measured by PSG, the Epworth Sleepiness Scale (ESS), the Pittsburgh Sleep Quality Index (PSQI), the Insomnia Severity Index (ISI) and the CT-scan-based tumor dimensions before treatment and 3 months after end of treatment (all secondary end points). In this prospective trial, 220 participants with comorbid OSA and HNSCC will be included. Participants with OSA will be allocated to aPAP-therapy or not using a 2:1 randomization. The aim is to investigate the possible role of OSA as well as the possible effect of aPAP in the aforementioned outcomes of these patients, with a power of 80% at the 5% significance level. Additionally, a possible effect of aPAP on oncologic outcome and / or tumor response during radiation because of the improved tumor and body oxygenation will also be evaluated.
Health condition or problem studied
- ICD10:
- G47.3 - Sleep apnoea
- ICD10:
- C14 - Malignant neoplasm of other and ill-defined sites in the lip, oral cavity and pharynx
- ICD10:
- C13 - Malignant neoplasm of hypopharynx
- Healthy volunteers:
- No Entry
Interventions, Observational Groups
- Arm 1:
- After 2:1 randomisation aPAP-therapy (auto-titrated positive airway pressure therapy) is used during radiation (6 weeks) and for the following 6 months. Masks should be worn for at least 5 hours / night.
- Arm 2:
- No aPAP-therapy during radiation and for the following 6 months
Endpoints
- Primary outcome:
- Symptomscale fatigue EORTC QLQ C 30 Before therapy (point in time 0), after surgery (after 2 weeks), after end of adjuvant therapy (after 8 weeks), during follow up (after 3 and 6 months)
- Secondary outcome:
- EORTC symptom scales Apnea / hypopnea index (AHI) Epworth Sleepiness Scale (ESS) Pittsburgh Sleep Quality Index (PSQI) Insomnia Severity Index (ISI) CT-scan-based tumor dimensions Before therapy, after surgery, after end of adjuvant therapy, during follow up
Study Design
- Purpose:
- Treatment
- Allocation:
- Randomized controlled study
- Control:
-
- Control group receives no treatment
- Phase:
- No Entry
- Study type:
- Interventional
- Mechanism of allocation concealment:
- No Entry
- Blinding:
- No
- Assignment:
- Parallel
- Sequence generation:
- No Entry
- Who is blinded:
- No Entry
Recruitment
- Recruitment Status:
- Recruiting ongoing
- Reason if recruiting stopped or withdrawn:
- No Entry
Recruitment Locations
- Recruitment countries:
-
- Germany
- Number of study centers:
- Monocenter study
- Recruitment location(s):
-
- University medical center Hals-Nasen-Ohrenklinik und Poliklinik Mainz
Recruitment period and number of participants
- Planned study start date:
- 2020-08-02
- Actual study start date:
- 2020-09-18
- Planned study completion date:
- No Entry
- Actual Study Completion Date:
- No Entry
- Target Sample Size:
- 220
- Final Sample Size:
- No Entry
Inclusion Criteria
- Sex:
- All
- Minimum Age:
- 18 Years
- Maximum Age:
- 100 Years
- Additional Inclusion Criteria:
- - Patients with cT2- cT4 head and neck cancer - Cancer localization oral, oropharynx, hypopharynx - Indication to surgery and adjuvant radiochemotherapy - Age 18 years and older
Exclusion Criteria
- Tracheostomy for the duration of the RCT - Laryngectomy - Missing informed consent - Congestive heart failure (EF < 30%) - Lung emphysema - BMI (body mass index) > 38 Kg/m²
Addresses
Primary Sponsor
- Address:
- Universitätsmedizin MainzLangenbeckstrasse 9955131 MainzGermany
- Telephone:
- 0049 6131 177361
- Fax:
- No Entry
- Contact per E-Mail:
- Contact per E-Mail
- URL:
- No Entry
- Investigator Sponsored/Initiated Trial (IST/IIT):
- Yes
Contact for Scientific Queries
- Address:
- Hals-Nasen-Ohrenklinik und Poliklinik der Universitätsmedizin MainzTilman HuppertzLangenbeckstrasse 9955131 MainzGermany
- Telephone:
- 0049 6131 177361
- Fax:
- No Entry
- Contact per E-Mail:
- Contact per E-Mail
- URL:
- No Entry
Contact for Public Queries
- Address:
- Universitätsmedizin MainzTilman HuppertzLangenbeckstrasse 155131 MainzGermany
- Telephone:
- 06131 17-0
- Fax:
- No Entry
- Contact per E-Mail:
- Contact per E-Mail
- URL:
- No Entry
Principal Investigator
- Address:
- Hals-Nasen-Ohrenklinik und Poliklinik der Universitätsmedizin MainzTilman HuppertzLangenbeckstrasse 9955131 MainzGermany
- Telephone:
- 0049 6131 177361
- Fax:
- No Entry
- Contact per E-Mail:
- Contact per E-Mail
- URL:
- No Entry
Sources of Monetary or Material Support
Institutional budget, no external funding (budget of sponsor/PI)
- Address:
- Universitätsmedzin MainzLangenbeckstrasse 155131 MainzGermany
- Telephone:
- 0049 6131 17-0
- Fax:
- No Entry
- Contact per E-Mail:
- Contact per E-Mail
- URL:
- No Entry
Ethics Committee
Address Ethics Committee
- Address:
- Ethik-Kommission bei der Landesärztekammer Rheinland-PfalzDeutschhausplatz 355116 MainzGermany
- Telephone:
- +49-6131-288220
- Fax:
- +49-6131-2882266
- Contact per E-Mail:
- Contact per E-Mail
- URL:
- No Entry
Vote of leading Ethics Committee
- Vote of leading Ethics Committee
- Date of ethics committee application:
- 2019-11-27
- Ethics committee number:
- 2019-14737
- Vote of the Ethics Committee:
- Approved
- Date of the vote:
- 2019-12-18
Further identification numbers
- Other primary registry ID:
- No Entry
- EudraCT Number:
- No Entry
IPD - Individual Participant Data
- Do you plan to make participant-related data (IPD) available to other researchers in an anonymized form?:
- Yes
- IPD Sharing Plan:
- Anonymised raw data will be supplied after request to the principal investigator.
Study protocol and other study documents
- Study protocols:
- No Entry
- Study abstract:
- No Entry
- Other study documents:
- No Entry
- Background literature:
- No Entry
- Related DRKS studies:
- No Entry
Publication of study results
- Planned publication:
- No Entry
- Publikationen/Studienergebnisse:
- No Entry
- Date of first publication of study results:
- No Entry
- DRKS entry published for the first time with results:
- No Entry
Basic reporting
- Basic Reporting / Results tables:
- No Entry
- Brief summary of results:
- No Entry